ViroPharma Starts Pivotal Camvia Study in Liver Transplant Patients
Posted on: Friday, 6 July 2007, 09:16 CDT
ViroPharma says its recently initiated second Phase III clinical study of Camvia in liver transplant patients is now open to patient recruitment.
The study will evaluate the prophylactic use of Camvia in patients undergoing a liver transplant procedure, and will be conducted in up to 60 US transplant centers. The first Phase III study of Camvia was initiated in September 2006 in patients undergoing a stem cell transplant.
ViroPharma's study will compare the efficacy, safety and tolerability of prophylactic use of Camvia versus oral ganciclovir when administered for up to 14 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of orthotopic liver transplants at high risk of developing CMV disease. The study also will evaluate the pharmacokinetics of Camvia in this subject population.
"The initiation of this second Phase III study is our latest milestone as we work towards our goal of making this important drug available for the more than 120,000 transplant patients throughout the world who are at risk of deadly CMV disease," commented Colin Broom, ViroPharma's chief scientific officer.
Source: Datamonitor
Related Articles
- Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
- Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
- Study; Older Transplant Patients Fare Well
- Stanford Study Finds Transplant Patient Thrives Two Years After Stopping Immunosuppressive Drugs
- Patient Recruitment Completed for Pivotal Phase III Study of Remoxy(TM)
- Patient Recruitment Completed for Pivotal Phase III Study of Remoxy; Clinical Results Expected Q4 2007
- AVANIR Announces Last Patient Enrolled in Neuropathic Pain Phase III Trial With Zenvia
- Vion Pharmaceuticals Reaches Midpoint of Patient Accrual to Cloretazine(R) (VNP40101M) Phase III Trial
- OMRIX Biopharmaceuticals Receives FDA Approval for Second Generation Fibrin Sealant, Evicel(TM), For Use in Liver Surgery; Submits Evicel Phase III Study to FDA for Expanded Indication in Peripheral Vascular Surgery
- Amarin Completes Target Patient Enrollment in North American Phase III Trial of Miraxion(TM) in Huntington's Disease
 |
 |
User Comments (0)
RSS Feeds